NEW YORK (
CHANGE IN RATINGS
was upgraded to buy at TheStreet Ratings.
(CVS - Get Report)
was downgraded at Cantor Fitzgerald to hold from buy. Valuation call, based on a $62 price target, Cantor said.
(FISV - Get Report)
was upgraded at Sterne Agee to buy from neutral. $120 price target. Company should deliver higher internal sales growth this year, given better end-market conditions, Sterne Agee said.
(FOSL - Get Report)
was downgraded at Citigroup to neutral from buy. Based on valuation and despite global growth opportunity, said Citi. Price target goes to $135.
was downgraded at DA Davidson to neutral from buy. $7.25 price target. Losses are broadening, DA Davidson said.
was upgraded at Credit Suisse to outperform from neutral. $90 price target. Company should benefit from competitor recalls, Credit Suisse said.
(MRO - Get Report)
was downgraded at Bank of America/Merrill Lynch to neutral. Valuation call, based on a $42 price target, BofA/Merrill said.
was downgraded to hold at TheStreet Ratings.
(YUM - Get Report)
was upgraded at Bank of America/Merrill Lynch to neutral from underperform. $79 price target. Market is more willing than expected to look through China issues, BofA/Merrill said.
Stock Comments / EPS Changes
numbers were cut at UBS. Estimates were reduced as backlog conversion is taking longer than expected, said UBS. Price target is reduced to $33.
numbers were increased at BMO Capital. Estimates were raised through 2014. Business turnaround is on course, BMO Capital said. Outperform rating and new $55 price target.
price target was raised at Citigroup to $285. The company remains on message with regard to positioning, organic growth, margins and capital returns, Citi said.
Charles River Laboratories
price target was raised at Jefferies to $57. Company is a relative value with an improving outlook in a CRO sector with very high investor enthusiasm, Jefferies said. Buy rating.
price target boosted at BMO Capital to $29. Expect strong earnings and guidance from the company on Aug. 14, BMO Capital said. Outperform rating.